XERS Stock Forecast & Price Target

Xeris Biopharma Holdings Inc demonstrated significant growth in its key product sales, with Recorlev achieving $22.6 million in revenue for 4Q24, a remarkable 131% increase from $9.8 million in 4Q23, and Gvoke sales rising by 25% to $23.3 million in the same period. The company reported a substantial increase of approximately 123% in new starts in 4Q24 compared to the previous year, reflecting an expanding prescriber base that potentially enhances future sales growth. Furthermore, the management's guidance for operating expenses increasing only in the mid-to-high single digits indicates stronger operating leverage than anticipated, contributing to a positive long-term outlook for the company's financial performance.

Xeris Biopharma Holdings reported a net loss of $0.03 per share for Q4 2024, with total revenues reaching $60.1 million, slightly surpassing Street estimates but indicating underlying financial challenges. The company faces significant risks associated with R&D and potential FDA setbacks, as well as competitive pressures from new generic entrants, which could impact future performance. Despite projecting 2025 revenues of $255-$275 million, the outlook remains cautious given the broader market and operational uncertainties.